Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
a technology of adenovirus and cardiomyocytes, which is applied in the direction of biocide, genetic material ingredients, animal repellents, etc., can solve the problems of low efficiency of cardiomyocyte transduction, limited therapeutic usefulness of this approach, and limited feasibility of adenovirus-mediated gene transfer
Inactive Publication Date: 2006-11-09
ARCH DEVMENT
View PDF6 Cites 2 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
[0009] Thus, this method provides a means of delivering AAV vectors in a stable and efficient manner. The vector can be infused by any convenient means and in conjunction with surgery or other cardiac procedure, if desired.
Problems solved by technology
However, the therapeutic usefulness of this approach has been limited by the low efficiency of cardiomyocyte transduction (0.1% to 1.0% of cardiomyocytes in the area of injection).
However, the feasibility of adenovirus-mediated gene transfer has been limited by immune responses to viral and foreign transgene proteins, which cause significant myocardial inflammation, eliminate virus-transduced cells within 30 days of infection, and thereby result in transient recombinant gene expression in immunocompetent hosts (Guzman et al.
However, since rAAV vectors used in gene therapy applications, unlike RDAd, do not encode viral proteins, the rAAV vectors have not been associated with immune responses to foreign transgene proteins.
Based on those results, infusing rAAV into the heart would have severely limited use as a vector for myocardial gene therapy.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
example
Intracoronary Infusion of rAAV
I. Methods:
Plasmids and Viruses
[0035] The structure of pAAVCMV-LacZ is shown in FIG. 1. AdCMV-LacZ and the E3-deleted adenovirus, Add1309, were propagated and purified as described (Barr 1994).
Propagation and Purification of rAAV
[0036] rAAV was prepared as described (Rolling et al. (1995) Mol. Biotechnol. 3:9-15) and purified by cesium chloride gradient centrifugation. Viral titer was assessed by a dot blot hybridization assay to determine the number of viral genomes per milliliter and by infecting HeLa cells with the virus and staining with X-gal 24 hours after infection. All viral preparations had titers of 1 to 2×1011 genomes / mL, and 2 to 3×109 infectious units (IU) / mL.
Intracoronary Perfusion with rAAV
[0037] Adult C57BL / 6 mouse hearts were perfused via the left carotid artery with cardioplegia solution (110 mmol / L NaCl, 25 mmol / L KCl, 22 mmol / L NaHCO3, 16 mmol / L MgCl2, 0.8 mmol / L CaCl2, 40 mmol / L glucose) at 4° C. until they stopped beatin...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| weight | aaaaa | aaaaa |
| body weight | aaaaa | aaaaa |
| area | aaaaa | aaaaa |
Login to View More
Abstract
This invention relates to the use of recombinant adeno-associated virus (rAAV) vectors to transduce cardiomyocytes in vivo by infusing the rAAV into a coronary artery or coronary sinus. rAAV infection is not associated with detectable myocardial inflammation or myocyte necrosis. Thus, rAAV is a useful vector for the stable expression of therapeutic genes in the myocardium and can be used to deliver genes for inducing angiogenesis, inhibiting angiogenesis, stimulating cell proliferation, inhibiting cell proliferation and / or treating or ameliorating other cardiovascular conditions.
Description
[0001] This application is a continuation-in-part application of provisional application U.S. Ser. No. 60 / 113,923, filed Dec. 28, 1998, which is incorporated by reference herein in its entirety.[0002] This work was supported in part by grants from the National Institutes of Health (DK-48997, AR-42895, and HL-54592) to Jeffrey M. Leiden.FIELD OF THE INVENTION [0003] The ability to stably and efficiently program recombinant gene expression in cardiomyocytes facilitates gene therapy approaches for a variety of cardiovascular diseases and conditions. Accordingly, this invention relates to the use of recombinant adeno-associated virus (rAAV) vectors to transduce cardiomyocytes in vivo by infusing the rAAV into a coronary artery or coronary sinus. For example, coronary artery perfusion of mouse hearts with a rAAV encoding the LacZ gene produced efficient transduction of cardiomyocytes which was stable for at least 8 weeks. Moreover, rAAV infection is not associated with detectable myocard...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K48/00C12N15/861
CPCA61K48/00C12N2750/14143C12N15/86
InventorLEIDEN, JEFFREY M.SVENSSON, ERIC
OwnerARCH DEVMENT